New England Journal of Medicine· 2020Q1· Clinical trial

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle et al.

7,315citations
Q1SCImago
2020year

Short summary

Combining atezolizumab and bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma compared to sorafenib.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hepatology

HepatologyMedicine